R&D channel feed

#ES­MO22: Trodelvy's long-await­ed sur­vival da­ta in breast can­cer are fi­nal­ly in — and bet­ter than ex­pect­ed

3 years ago

#ES­MO22: Bris­tol My­ers spells out kid­ney can­cer flop for Op­di­vo/Yer­voy com­bo — but can a triplet catch on?

3 years ago

#ES­MO22: Out­side liv­er can­cer, Keytru­da notch­es key win in neoad­ju­vant set­ting but flops in head and neck tu­mors

3 years ago

#ES­MO22: Mi­rati vs. Am­gen: Scrap­py KRAS G12C con­tender out­per­forms its gi­ant ri­val in col­orec­tal can­cer

3 years ago

In­te­gral Mol­e­c­u­lar's off-tar­get pro­tein bind­ing ar­ray nabs first spot in FDA pi­lot to speed new drug de­vel­op­ment tools

3 years ago
FDA+

Paci­ra looks to ex­pand use of Ex­par­el for pain re­lief fol­low­ing knee re­place­ment surgery

3 years ago

Shoot­ing for a heav­i­ly pre-treat­ed niche can­cer mar­ket, Bi­cy­cle re­veals a 'mixed' da­ta cut

3 years ago

Boehringer In­gel­heim preps FDA sub­mis­sion with new da­ta in rare pe­di­atric lung dis­ease

3 years ago
Pharma

Eye-fo­cused Iver­ic Bio re­ports pos­i­tive PhI­II read­out as shares surge, FDA fil­ing planned

3 years ago

Up­dat­ed: Athi­ra plots an Alzheimer's come­back af­ter scan­dal, PhII fail — and hints at pos­si­ble ac­cel­er­at­ed ap­proval pitch

3 years ago
FDA+

#ES­MO22: Dizal touts win in niche NSCLC pop­u­la­tion cor­nered by Take­da, J&J

3 years ago
China

PhRMA and BIO seek changes in FDA’s guid­ance to mit­i­gate drug short­ages

3 years ago
Manufacturing

Small Is­raeli biotech flops a PhI­II test in post-surgery in­fec­tions — shares crushed

3 years ago

As Fiona Mar­shall makes her move to NI­BR, Mer­ck is ready with a key re­place­ment play­er

3 years ago
People

Arc­turus touts $63M BAR­DA award for new mR­NA in­fluen­za vac­cine, hop­ing to prep against fu­ture pan­demics

3 years ago
Financing

One week af­ter Take­da walked away, Finch faces sec­ond round of lay­offs, pipeline prun­ing

3 years ago
People

Ahead of #ES­MO22: An­a­lysts poke at Gilead’s Trodelvy OS; Am­gen and Mi­rati try to out-KRAS each oth­er

3 years ago

In wake of third straight mid-stage set­back, Anap­tys­Bio looks to punt IL-36 drug — even as PhI­II goes on

3 years ago

A $280M life sci­ence fa­cil­i­ty is com­ing to Col­orado as it gains more in­ter­est from biotech de­vel­op­ers

3 years ago
Pharma

Af­ter dis­ap­point­ing Wall Street last year, De­nali touts new bio­mark­er da­ta hop­ing to forge clear path to FDA

3 years ago
FDA+

Im­muno­Gen push­es read­out of rare blood can­cer tri­al to 2024

3 years ago

De­spite mar­ket head­winds, life sci­ences re­al es­tate is still on the rise, new re­port says

3 years ago

Am­gen posts terse up­date on PhI­II Lumakras win — but just how big?

3 years ago
Pharma

Trapped in Nas­daq’s biotech base­ment, Co­di­ak’s Doug Williams lays out a sur­vival plan: chop­ping jobs, PhII plans

3 years ago
People
First page Previous page 120121122123124125126 Next page Last page
A service from the Financial Times